Results 171 to 180 of about 41,988 (241)

Ressó, núm. 006 [PDF]

, 1989
openaire  

006 結語

006 結語
openaire  

Some of the next articles are maybe not open access.

Related searches:

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
C. Robert, M. Carlino, C. McNeil, A. Ribas, J. Grob, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, James Anderson, C. Krepler, Dmitri O. Grebennik, G. Long   +18 more
semanticscholar   +1 more source

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)

Journal of Clinical Oncology, 2022
PURPOSE The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors.
J. Tanyi, L. Randall, S. Chambers, K. Butler, Ira S. Winer, C. Langstraat, E. Han, A. Vahrmeijer, H. Chon, M. Morgan, M. Powell, J. Tseng, Alexis Lopez, R. Wenham   +13 more
semanticscholar   +1 more source

Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B

Hepatology, 2022
Background and Aims: In the treatment of chronic hepatitis B (CHB) infection, stimulation of innate immunity may lead to hepatitis B virus (HBV) cure.
Cong Xu, Jieqing Fan, Danyang Liu, Aimaier Tuerdi, Juanjuan Chen, Yuning Wei, Yanfang Pan, H. Dang, Xiong Wei, A. Yousif, J. Yogaratnam, Qiong Zhou, H. Lichenstein, Tian Xu   +13 more
semanticscholar   +1 more source

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.

European Journal of Cancer, 2020
BACKGROUND CONKO-006 was designed for patients with pancreatic adenocarcinoma with postsurgical R1 residual status to evaluate the efficacy and safety of the combination of gemcitabine and sorafenib (GemSorafenib) compared with those of gemcitabine ...
M. Sinn, T. Liersch, H. Riess, K. Gellert, P. Stübs, D. Waldschmidt, F. Lammert, G. Maschmeyer, W. Bechstein, M. Bitzer, C. Denzlinger, R. Hofheinz, U. Lindig, M. Ghadimi, A. Hinke, J. Striefler, U. Pelzer, S. Bischoff, M. Bahra, H. Oettle   +19 more
semanticscholar   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of Oncology
BACKGROUND Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented.
G. V. Long, M. Carlino, C. McNeil, A. Ribas, C. Gaudy-Marqueste, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, C. Robert   +18 more
semanticscholar   +1 more source

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

, 2020
10013Background: 5-year follow-up of the phase 3 KEYNOTE-006 study (NCT01866319) showed pembro improved OS vs ipilimumab (ipi) in patients (pts) with advanced melanoma.
G. Long, J. Schachter, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, A. Ribas, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, E. Jensen, C. Krepler, S. Diede, C. Robert   +19 more
semanticscholar   +1 more source

Anti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated MyD88/ NF-κB Signaling.

CNS and Neurological Disorders - Drug Targets
INTRODUCTION Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau ...
Haiyun Chen, Xiao Chang, Jiemei Zhou, Guiliang Zhang, Jiehong Cheng, Zaijun Zhang, Jieyu Xing, Chunyan Yan, Zheng Liu   +8 more
semanticscholar   +1 more source

A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.

Molecular Cancer Therapeutics
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, and KRAS mutations occur in 25-30% of NSCLC. Our approach to developing a therapeutic with the potential to target KRAS mutant NSCLC was to identify a new target involved ...
C. Cina, Bharat Majeti, Zhihong O'Brien, Li Wang, J. Clamme, R. Adami, K. Tsang, Jens Harborth, W. Ying, Sonya Zabludoff   +9 more
semanticscholar   +1 more source